Die Givaudan SMI-Aktie steigt auf ein 11-Wochen-Hoch nach einem Analystenaufschwung

The stock of Givaudan, a leading Swiss company in the field of fragrance and flavouring, experienced a strong upturn last week. On Friday evening, it reached its highest level in eleven weeks with a gain of 6.8 percent to CHF 3,463, outperforming all other stocks of the Swiss Market Index (SMI) by 1.6 percent. The SMI itself recorded a moderate gain of 1.6 percent. This development follows a prolonged weakness phase during which the stock was largely ignored between July and September. Since its peak of CHF 4,670 two years ago, Givaudan has lost around 25 percent in value, making it an undervalued stock in the SMI. Analysts adjusted their price targets and value estimates last week, which contributed to the upward trend. Barclays raised its price target from CHF 3,300 to CHF 3,450, but kept its neutral rating. JPMorgan confirmed its overweight rating and raised its price target from CHF 3,600 to CHF 3,700. The Citigroup maintained its neutral rating, but adjusted its price target from CHF 3,150 to CHF 3,450. The analysts are already looking ahead to the first quarterly report for 2026 and expect positive developments in both business areas. JPMorgan raised its forecast for organic revenue growth and estimates earnings per share (EPS) for 2026 at CHF 135.09 and for 2027 at CHF 141.81. This is in contrast to the forecasts of the Zürcher Kantonalbank (ZKB), which expects an EPS of CHF 109.90 for 2026 and an EPS of CHF 133.30 for 2027. Despite these positive signals, the stock is already close to the average price target of CHF 3,458. The analyst ratings vary: nine experts recommend Givaudan for purchase, eleven hold the position neutral, and three advise selling. These recommendations are not final and could change by the next investor meeting of the week. In addition to Givaudan, other health care and finance stocks showed positive developments last week: Galderma, Novartis, Lonza and Sandoz rose by 2.9 to 4.1 percent, while Swiss Re gained 3.4 percent. In contrast, Zurich Insurance, UBS and Partners Group lost between 2.2 and 2.4 percent in value.